301 related articles for article (PubMed ID: 24602388)
1. Incretins and the intensivist: what are they and what does an intensivist need to know about them?
Plummer MP; Chapman MJ; Horowitz M; Deane AM
Crit Care; 2014 Feb; 18(2):205. PubMed ID: 24602388
[TBL] [Abstract][Full Text] [Related]
2. Dysglycaemia in the critically ill - significance and management.
Deane AM; Horowitz M
Diabetes Obes Metab; 2013 Sep; 15(9):792-801. PubMed ID: 23368662
[TBL] [Abstract][Full Text] [Related]
3. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
[TBL] [Abstract][Full Text] [Related]
4. Incretin-based therapies for type 2 diabetes mellitus: a review of direct comparisons of efficacy, safety and patient satisfaction.
Russell S
Int J Clin Pharm; 2013 Apr; 35(2):159-72. PubMed ID: 23263796
[TBL] [Abstract][Full Text] [Related]
5. A pilot study of the efficacy of miglitol and sitagliptin for type 2 diabetes with a continuous glucose monitoring system and incretin-related markers.
Kishimoto M; Noda M
Cardiovasc Diabetol; 2011 Dec; 10():115. PubMed ID: 22189184
[TBL] [Abstract][Full Text] [Related]
6. Update on incretin hormones.
Phillips LK; Prins JB
Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
[TBL] [Abstract][Full Text] [Related]
7. Comparing incretin-based therapies. Evaluating GLP-1 agonists and DPP-4 inhibitors for type 2 diabetes mellitus.
Urquhart BS
Adv NPs PAs; 2010 Oct; 1(2):38-44. PubMed ID: 21299149
[No Abstract] [Full Text] [Related]
8. Incretin Physiology and Pharmacology in the Intensive Care Unit.
Plummer MP; Hermanides J; Deane AM
Crit Care Clin; 2019 Apr; 35(2):341-355. PubMed ID: 30784614
[TBL] [Abstract][Full Text] [Related]
9. Incretins: their physiology and application in the treatment of diabetes mellitus.
Tasyurek HM; Altunbas HA; Balci MK; Sanlioglu S
Diabetes Metab Res Rev; 2014 Jul; 30(5):354-71. PubMed ID: 24989141
[TBL] [Abstract][Full Text] [Related]
10. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
11. Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus.
Stephens JW; Bodvarsdottir TB; Wareham K; Prior SL; Bracken RM; Lowe GD; Rumley A; Dunseath G; Luzio S; Deacon CF; Holst JJ; Bain SC
Diabetes Res Clin Pract; 2011 Nov; 94(2):199-206. PubMed ID: 21835486
[TBL] [Abstract][Full Text] [Related]
12. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Nauck M
Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
[TBL] [Abstract][Full Text] [Related]
13. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
[TBL] [Abstract][Full Text] [Related]
14. The role of incretin-based therapies in the management of type 2 diabetes.
Bandyopadhyay P
Drug News Perspect; 2009 Nov; 22(9):559-67. PubMed ID: 20072733
[TBL] [Abstract][Full Text] [Related]
15. Incretin-based treatment of type 2 diabetes: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Deacon CF
Diabetes Obes Metab; 2007 Sep; 9 Suppl 1():23-31. PubMed ID: 17877544
[TBL] [Abstract][Full Text] [Related]
16. Updates of incretin-related drugs for the treatment of type 2 diabetes.
Araki H; Matsumura T; Furukawa N; Araki E
J Diabetes Investig; 2023 Feb; 14(2):189-192. PubMed ID: 36373430
[TBL] [Abstract][Full Text] [Related]
17. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.
Moore KB; Saudek CD
Am J Ther; 2008; 15(5):484-91. PubMed ID: 18806525
[TBL] [Abstract][Full Text] [Related]
19. Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus.
Groeneveld ON; Kappelle LJ; Biessels GJ
J Diabetes Investig; 2016 Jan; 7(1):5-16. PubMed ID: 26816596
[TBL] [Abstract][Full Text] [Related]
20. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
